ACMI (Southborough, Massachusetts), which manufactures diagnostic and therapeutic endoscopic instrumentation products and systems, said that its global R&D group has developed the world's smallest digital camera and video color sensor. The company said it plans to incorporate this sensor technology into its line of advanced endoscopic medical devices. ACMI's initial development was a 1 mm color CMOS (complimentary metal-oxide silicon) digital output video sensor. The color sensor operates in both full-motion and still-capture video modes. The company also has designed a micro-miniature lens system that integrates directly into the sensor. By using its digital CMOS technology, the sensor can be tailored to produce high-resolution full-screen images in both normal and low-light situations.
GE Healthcare (Waukesha, Wisconsin) said its next-generation volume computed tomography (CT) scanner, the LightSpeed VCT, is being used to image the brains of stroke patients at University of Michigan Health System (Ann Arbor, Michigan). GE also said its Stroke WorkUp application was featured at the American Society of Neuroradiology annual meeting in Toronto. In a single rotation, the LightSpeed VCT creates 64 submillimeter images, totaling 40 mm of anatomical coverage, which are combined to form a 3-D view of the patient's anatomy for the physician to analyze. This speed and resolution are required for perfusion studies, to provide information to help doctors make an accurate and timely diagnosis of stroke, and to help doctors determine the extent of stroke damage.
NanoLogix (Sharon, Pennsylvania), a nanobiotechnology company developing technologies for the production of bacteria and disease testing kits, reported that its DNA extraction system and protocol is both easier, due to fewer steps, and quicker, taking significantly less time than standard spin column extraction methods. The NanoLogix MycoExtract Buffer provides for the extracted DNA to be precipitated and resuspended in water. The extracted DNA in the MycoExtract Buffer can be used directly for molecular procedures such as polymerase chain reaction, which also results in additional time savings.
Quidel (San Diego), a provider of rapid point-of-care diagnostic tests, reported that it has received third-party validation of its QuickVue Influenza A+B test in a study presented at the 21st annual Clinical Virology Symposium and annual meeting of the Pan American Society for Clinical Virology. The study, conducted by scientists at the University of Rochester Medical Center (Rochester, New York), found that the QuickVue Influenza A+B assay demonstrated the highest analytical sensitivity among the four tests examined for their effectiveness in detecting the flu. The results showed that the QuickVue Influenza A+B test was more sensitive than the other tests 95% of the time.
TriPath Imaging (Burlington, North Carolina) and Ventana Medical Systems (Tucson, Arizona) reported that TriPath Imaging has received 510(k) clearance from the FDA for the Ventana Image Analysis System when used with tissues stained for Estrogen Receptor (ER) and Progesterone Receptor (PR). Ventana will globally market the Ventana-branded interactive histology image analysis system from TriPath Imaging. ER and PR analysis aids in the management of breast cancer.
Xenomics (New York), a developer of medical DNA technologies, said it has filed a provisional patent with the U.S. Patent and Trademark Office connected to its discovery of methods to detect the genetic abnormality Down syndrome through the company's Transrenal-DNA (Tr-DNA) detection technology. The Xenomics provisional patent provides for methods that use a comparative analysis of carefully selected fragments of DNA contained in Chromosome 21, where the abnormality in Down syndrome patients occurs. Among certain of these fragments, called CpG islands, very specific markers referred to as methylation sites, have been found which are clearly distinct from normal chromosomal DNA. The company said the invention is expected to be useful for diagnosing the presence or absence of Down syndrome using DNA samples taken from maternal bodily fluids, including urine, plasma, serum and amniotic fluid. Xenomics also said it will begin human clinical trials on prenatal tests based on its Down syndrome detection technology, conducted in collaboration with North Shore-Long Island Jewish Health System (Great Neck, New York) and Eastern Virginia Medical School (Norfolk, Virginia).